T2 Biosystems is developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance technology and eliminates the need for costly and time consuming sample preparation. T2 Biosystems’ platform technology has been validated in multiple published journal articles and has shown to accurately detect viruses, bacteria, proteins, hormones, DNA, small molecules and other diagnostic targets in a variety of liquid specimens including blood, serum, plasma and urine.

Flagship Partner Doug Levinson was Founding CEO and serves as Director on the Board.

www.t2biosystems.com